Fexuprazan Hydrochloride CAS No.: 1902954-87-3
Fexuprazan Hydrochloride (HCl) is a next-generation Potassium-Competitive Acid Blocker (P-CAB) API developed as a fast-acting and durable alternative to conventional Proton Pump Inhibitors (PPIs).
What Is Fexuprazan Hydrochloride?
Fexuprazan Hydrochloride (CAS No. 1902954-87-3) is a pharmaceutical active ingredient (API) classified as a Potassium-Competitive Acid Blocker (P-CAB). It is designed to suppress gastric acid secretion and is used in the treatment of acid-related gastrointestinal disorders, most notably gastroesophageal reflux disease (GERD) and erosive esophagitis.
|
Items |
Specifications |
|
Product Name |
Fexuprazan Hydrochloride |
|
CAS Number |
1902954-87-3 |
|
Molecular Formula |
C₂₄H₂₅F₂N₃O₂ |
|
Appearance |
White to off-white crystalline powder |
|
Purity (HPLC) |
99.0% |
|
Storage |
Store in a cool, dry place; keep away from strong light |
Mechanism of Action
One of the most frequent inquiries we receive is: "Is Fexuprazan a PPI?" The answer is no. While both reduce stomach acid, the Fexuprazan mechanism of action is distinct:
Competitive Binding: It competitively inhibits the $H^+/K^+$-ATPase pump without requiring acid activation.
Rapid Effect: Unlike PPIs, which may take days to reach full efficacy, Fexuprazan provides nearly immediate acid suppression.
Stability: It maintains a stable pH level in the stomach for longer durations, which is a key advantage when comparing Fexuprazan vs Pantoprazole.
Uses & Applications
Fexuprazan HCl API is widely used in formulations for:
Gastroesophageal Reflux Disease (GERD)
Erosive Esophagitis
Gastric and Duodenal Ulcers
Acid-related disorders requiring long-term maintenance therapy
Typical Fexuprazan Dose:
Standard clinical dosing is 40 mg once daily, though API flexibility allows development of multiple dosage strengths.
Common Side Effects
Fexuprazan Hydrochloride is generally well tolerated. Reported adverse effects are mild to moderate and may include:
Diarrhea or constipation
Nausea
Abdominal discomfort
Headache
Safety data supports its use in both short-term healing and maintenance regimens.
Fexuprazan vs Pantoprazole
| Feature | Fexuprazan | Pantoprazole |
|---|---|---|
| Drug Class | Potassium-Competitive Acid Blocker (P-CAB) | Proton Pump Inhibitor (PPI) |
| Acid Activation Required | No | Yes |
| Onset of Action | Rapid (within hours) | Delayed (3–5 days for full effect) |
| Meal Dependency | Meal-independent | Must be taken before meals |
| Nighttime Acid Control | Strong | Limited in some patients |
| CYP2C19 Influence | Minimal | Significant |
| Typical Dose | 40 mg once daily | 40 mg once daily |
Fexuprazan vs Vonoprazan
Fexuprazan and Vonoprazan both belong to the class of Potassium-Competitive Acid Blockers (P-CABs) and represent next-generation alternatives to traditional Proton Pump Inhibitors (PPIs). While they share the same core mechanism, there are important differences in pharmacokinetics, clinical positioning, and formulation strategy.
Drug Class Overview
| Feature | Fexuprazan | Vonoprazan |
|---|---|---|
| Drug Class | P-CAB | P-CAB |
| Acid Activation Required | No | No |
| Binding to H⁺/K⁺-ATPase | Competitive, reversible | Competitive, reversible |
| Onset of Action | Rapid | Rapid |
| Meal Dependency | Meal-independent | Meal-independent |
Both agents directly block the gastric proton pump, allowing for immediate and sustained acid suppression.
As a trusted Fexuprazan Hydrochloride API supplier, manufacturer, and wholesale exporter, we are committed to delivering consistent quality and regulatory-ready materials for global pharmaceutical markets.
Message us to get your personalized quotation within 24 hours.
-
Whatsapp:+852 6736 4057
-
Telegram:@hinovopept
-
Email:novopept@gmail.com
Hot Tags: fexuprazan hydrochloride cas no.: 1902954-87-3, China fexuprazan hydrochloride cas no.: 1902954-87-3 manufacturers, suppliers, factory
Send Inquiry
